Corrie P, Terheyden P, ten Tije AJ, et al. A prospective observational safety study of patients (pts) with BRAFV600E-mutated unresectable or metastatic melanoma (MM) treated with vemurafenib (VEM) (Zelboraf Safety Study [ZeSS]): final results. SMR 2017, abstract P17-7.
Positief BOM-advies voor pembrolizumab bij gemetastaseerd colorectaal carcinoom
feb 2021 | Immuuntherapie, Maag-darm-leveroncologie